Clinical and prognostic significance of high-mobility group box-1 in human gliomas

Wang,Xin‑Jun; Zhou,Shao‑Long; Fu,Xu‑Dong; Zhang,Yan‑Yan; Liang,Bo; Shou,Ji‑Xin; Wang,Jian‑Ye; Ma,Jian

doi:10.3892/etm.2014.2089

Clinical and prognostic significance of high-mobility group box-1 in human gliomas

Authors:
- Xin‑Jun Wang
- Shao‑Long Zhou
- Xu‑Dong Fu
- Yan‑Yan Zhang
- Bo Liang
- Ji‑Xin Shou
- Jian‑Ye Wang
- Jian Ma
View Affiliations

Affiliations: Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Pathophysiology, College of Basic Medical Sciences of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: November 25, 2014 https://doi.org/10.3892/etm.2014.2089
Pages: 513-518

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of this study was to explore the expression and the clinical and prognostic significance of high‑mobility group box‑1 (HMGB1) in human gliomas. The expression of HMGB1 in 15 samples of normal brain tissue and 65 samples of different‑grade glioma tissue was assayed using immunohistochemistry and western blot analysis. The associations between the differences in expression and pathology grades were analyzed statistically. Uni‑ and multivariate analyses were performed to investigate the prognostic value of HMGB1 expression and its expression levels. The positive rates of HMGB1 expression in normal brain and glioma tissue were 20.0% (3/15) and 76.9% (50/65), respectively. The expression of HMGB1 in glioma tissue was higher than that in normal tissue (P<0.05). The positive rates of HMGB1 expression in low‑grade gliomas (LGGs, grades I and II) and high‑grade gliomas (HGGs, grades III and IV) were 63.0% (17/27) and 86.8% (33/38), respectively, and the positive rates in HGG were higher than those in LGG (P=0.024). Western blot analysis showed that HMGB1 was also expressed in normal brain tissue. The expression levels in HGG were significantly higher than those in LGG (P<0.001). HMGB1‑positive patients had significantly shorter overall survival times compared with HMGB1‑negative patients (P=0.026). Increasing levels of HMGB1 expression significantly correlated with reduced survival times when all patients with glioma were considered (P=0.045). In conclusion, HMGB1 positivity and protein expression levels are of significant clinical and prognostic value in human gliomas. Detecting HMGB1 in human gliomas may be useful for assessing the degree of malignancy, and HMGB1 would appear to be a promising target in the clinical management of patients with glioma.

View Figures

View References

1	Kong BH, Park NR, Shim JK, et al: Isolation of glioma cancer stem cells in relation to histological grades in glioma specimens. Childs Nerv Syst. 29:217–229. 2013. View Article : Google Scholar
2	Chamberlain MC: Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy. Int J Clin Pract. 67:1225–1227. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kim SM, Woo JS, Jeong CH, et al: Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma. Stem Cells Transl Med. 3:172–182. 2014. View Article : Google Scholar : PubMed/NCBI
4	Stros M: HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta. 1799:101–113. 2010. View Article : Google Scholar : PubMed/NCBI
5	Belgrano FS, de Abreu da Silva IC, Bastos de Oliveira FM, et al: Role of the acidic tail of high mobility group protein B1 (HMGB1) in protein stability and DNA bending. PLoS One. 8:e795722013. View Article : Google Scholar : PubMed/NCBI
6	Fahmueller YN, Nagel D, Hoffmann RT, et al: Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer. 132:2349–2358. 2013. View Article : Google Scholar
7	Stoetzer OJ, Fersching DM, Salat C, et al: Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol. 34:81–90. 2013. View Article : Google Scholar
8	Gupta P, Ghosh S, Nagarajan A, et al: β-defensin-3 negatively regulates TLR4-HMGB1 axis mediated HLA-G expression in IL-1β treated glioma cells. Cell Signal. 25:682–689. 2013. View Article : Google Scholar
9	Brat DJ, Scheithauer BW, Fuller GN and Tihan T: Newly codified glial neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma. Brain Pathol. 17:319–324. 2007. View Article : Google Scholar : PubMed/NCBI
10	Goodenberger ML and Jenkins RB: Genetics of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
11	Sahgal A, Ironside SA, Perry J, et al: Factors influencing overall survival specific to adult low-grade astrocytoma: a population-based study. Clin Oncol (R Coll Radiol). 25:394–399. 2013. View Article : Google Scholar
12	Zhang X, Yang H, Gong B, et al: Combined gene expression and protein interaction analysis of dynamic modularity in glioma prognosis. J Neurooncol. 107:281–288. 2012. View Article : Google Scholar
13	Huang J, Ni J, Liu K, et al: HMGB1 promotes drug resistance in osteosarcoma. Cancer Res. 72:230–238. 2012. View Article : Google Scholar
14	Youn JH and Shin JS: Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol. 177:7889–7897. 2006. View Article : Google Scholar : PubMed/NCBI
15	Schlueter C, Weber H, Meyer B, et al: Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol. 166:1259–1263. 2005. View Article : Google Scholar : PubMed/NCBI
16	Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta. 1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
17	Guerriero JL, Ditsworth D, Catanzaro JM, et al: DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity. J Immunol. 186:3517–3526. 2011. View Article : Google Scholar : PubMed/NCBI
18	Hui L, Yao Y, Wang S, et al: Inhibition of Janus kinase 2 and signal transduction and activator of transcription 3 protect against cecal ligation and puncture-induced multiple organ damage and mortality. J Trauma. 66:859–865. 2009. View Article : Google Scholar : PubMed/NCBI
19	Wagner KU and Schmidt JW: The two faces of Janus kinases and their respective STATs in mammary gland development and cancer. J Carcinog. 10:322011. View Article : Google Scholar
20	Diaz T, Navarro A, Ferrer G, et al: Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS One. 6:e188562011. View Article : Google Scholar : PubMed/NCBI
21	Rauvala H and Rouhiainen A: Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim Biophys Acta. 1799:164–170. 2010. View Article : Google Scholar
22	Ohmori H, Luo Y and Kuniyasu H: Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer. Expert Opin Ther Targets. 15:183–193. 2011. View Article : Google Scholar : PubMed/NCBI
23	Bassi R, Giussani P, Anelli V, et al: HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration. J Neurooncol. 87:23–33. 2008. View Article : Google Scholar
24	Tang D, Kang R, Cheh CW, et al: HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 29:5299–5310. 2010. View Article : Google Scholar : PubMed/NCBI
25	Wittwer C, Boeck S, Heinemann V, et al: Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer. 133:2619–2630. 2013.PubMed/NCBI
26	Naglova H and Bucova M: HMGB1 and its physiological and pathological roles. Bratisl Lek Listy. 113:163–171. 2012.PubMed/NCBI
27	Kostova N, Zlateva S, Ugrinova I and Pasheva E: The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem. 337:251–258. 2010. View Article : Google Scholar
28	Jube S, Rivera ZS, Bianchi ME, et al: Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res. 72:3290–3301. 2012. View Article : Google Scholar : PubMed/NCBI
29	Martins I, Kepp O, Menger L, et al: Fluorescent biosensors for the detection of HMGB1 release. Methods Mol Biol. 1004:43–56. 2013. View Article : Google Scholar : PubMed/NCBI
30	Yang GL, Zhang LH, Bo JJ, et al: Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 106:57–61. 2012. View Article : Google Scholar : PubMed/NCBI